Tuesday, June 21, 2016

IsoRay touts brachytherapy brain cancer trial

IsoRay (NYSE:ISR) today released results from a prospective trial of intraoperative brachytherapy using its Cesium-131 brachytherapy seeds, touting that 95% of treated tumors showed no regrowth at the operative site.
The study examined the use of the …

No comments:

Post a Comment